A common, safe, inexpensive drug may significantly improve how well an important class of cancer therapies works
A medication long trusted to quiet the pressure in human arteries may now be asked to join the fight against one of humanity's oldest adversaries. Researchers at Dartmouth Cancer Center have discovered that telmisartan, a common and inexpensive blood pressure drug, meaningfully amplifies the tumor-killing power of PARP inhibitor therapies by making cancer cells more vulnerable to DNA damage and more visible to the immune system. The finding matters not only for what it might offer patients whose cancers currently resist these treatments, but for what it suggests about the hidden potential of medicines already woven into everyday life.
- PARP inhibitors have long been constrained by a narrow patient pool — only tumors with specific DNA repair defects respond, leaving many patients without options.
- Telmisartan breaks that constraint by flooding cancer cells with greater DNA damage and triggering type I interferons, the immune system's own alarm bells, while stripping tumors of a key molecular disguise.
- Critically, no other drug in telmisartan's class replicates this effect, making it a singular and unexplained outlier that researchers are racing to understand.
- Two clinical trials — one in metastatic prostate cancer, one in platinum-resistant ovarian cancer — are already enrolling patients, with the first prostate cancer participant showing what investigators called an exceptional early response.
- The broader implication is still unfolding: early data suggest telmisartan may also amplify chemotherapy and immunotherapy, hinting at a mechanism that could reach well beyond PARP inhibitors.
A blood pressure drug found in millions of medicine cabinets may have a second calling. Scientists at Dartmouth Cancer Center have discovered that telmisartan, routinely prescribed for hypertension, can substantially strengthen the effectiveness of olaparib and other PARP inhibitor cancer therapies — a finding published in the Journal for ImmunoTherapy of Cancer that could expand treatment to patients currently left behind.
PARP inhibitors exploit a flaw in cancer cells: their impaired ability to repair damaged DNA. They work well against tumors carrying BRCA mutations or similar defects, but many cancers lack these vulnerabilities, and others develop resistance over time. Senior author Tyler Curiel and his team asked whether telmisartan might push past those limits.
In laboratory studies, the combination of telmisartan and olaparib inflicted more DNA damage on tumors than olaparib alone. It also ignited a stronger immune response — boosting type I interferons that signal the immune system to attack, while reducing PD-L1, a protein tumors use to hide from immune detection. The drug, Curiel explained, doesn't simply make olaparib work harder; it makes the tumor more exposed and more vulnerable to the body's own defenses.
What makes the discovery particularly striking is that telmisartan appears to stand alone. Researchers tested other drugs in the same class — angiotensin II receptor blockers — and found the cancer-enhancing effect only with telmisartan. Its low cost, oral dosing, and tolerability even in people without hypertension make it an unusually practical candidate for rapid clinical testing.
Two trials are already underway. One pairs telmisartan with olaparib in men with metastatic, castration-resistant prostate cancer — the first patient enrolled showed what Curiel called an exceptional response. A second trial has just admitted its first participant with platinum-resistant ovarian cancer. Researchers are also gathering early evidence that telmisartan may enhance chemotherapy and immunotherapy through similar mechanisms, suggesting the reach of this discovery may extend well beyond PARP inhibitors.
A blood pressure medication sitting in millions of medicine cabinets may have a second job to do. Researchers at Dartmouth Cancer Center have found that telmisartan, a drug prescribed routinely for hypertension, can substantially strengthen the cancer-fighting power of olaparib, a targeted therapy that belongs to a class of drugs called PARP inhibitors. The discovery, published in the Journal for ImmunoTherapy of Cancer, opens a path toward helping patients whose tumors currently resist these expensive, specialized treatments.
PARP inhibitors work by exploiting a weakness in cancer cells—their broken ability to repair damaged DNA. The drugs have proven effective against certain tumors, particularly those carrying BRCA mutations or other DNA repair defects. But the limitation is real: many cancers lack these vulnerabilities, which means many patients cannot benefit. Others develop resistance over time. Tyler Curiel, the study's senior author, and his team set out to ask whether telmisartan might expand the reach of these drugs beyond their current boundaries.
In laboratory experiments, tumors treated with both telmisartan and olaparib sustained more DNA damage than tumors exposed to olaparib alone. The combination also triggered a stronger immune response. Specifically, it ramped up production of type I interferons—molecules that act as a biological alarm system, alerting the immune system to find and destroy cancer cells. Telmisartan also reduced levels of PD-L1, a protein that helps tumors hide from immune attack. The mechanism, Curiel explained, appears to hinge on this immune activation. The drug does not simply make olaparib work harder; it makes the tumor more visible and vulnerable to the body's own defenses.
What makes this finding unusual is that telmisartan stands alone among blood pressure medications in this regard. The researchers tested other drugs in the same class—angiotensin II receptor blockers, or ARBs—and found the cancer-boosting effect only with telmisartan. The drug is inexpensive, taken by mouth, and well tolerated even in people without high blood pressure. Those qualities make it an unusually practical candidate for rapid testing in actual patients.
Two clinical trials are already underway. One is pairing telmisartan with olaparib in men with metastatic, castration-resistant prostate cancer. The first patient enrolled showed what Curiel described as an exceptional response. A second trial is examining the combination in platinum-resistant ovarian cancer and has just admitted its first participant. Curiel noted that the team has also gathered promising data suggesting telmisartan may enhance the effectiveness of chemotherapy and immunotherapy across multiple cancer types through similar mechanisms. The next phase will determine whether these laboratory findings translate into real clinical benefit—whether the combination can help more patients respond to treatment and whether it can overcome the resistance that eventually develops.
Citas Notables
This study shows that a common, safe, tolerable, convenient, and inexpensive drug may significantly improve how well an important class of cancer therapies works— Tyler Curiel, senior author, Dartmouth Cancer Center
We are encouraged by what we are seeing so far. Our goal is to determine whether this combination approach can help more patients benefit from greater effectiveness of PARP inhibitors and other cancer treatment classes— Tyler Curiel
La Conversación del Hearth Otra perspectiva de la historia
Why does telmisartan work when other blood pressure drugs in the same family don't?
That's the question we're still working to fully answer. The mechanism appears to be specific to how telmisartan interacts with the immune system in the tumor environment. It's not just about lowering blood pressure—something about this particular drug's structure or how it behaves inside cancer cells triggers type I interferon production in a way the others don't.
So you're saying a patient could be taking this for their hypertension and simultaneously getting a cancer therapy boost?
Exactly. That's part of what makes this so compelling. There's no new drug to develop, no new side effect profile to worry about. The drug is already in the world, already proven safe. We're just discovering it has another job.
What happens to patients whose tumors don't have those DNA repair defects—the ones PARP inhibitors normally can't touch?
That's the whole point. In our preclinical work, telmisartan made those tumors sensitive to olaparib even without the classic DNA repair problems. It's like the drug is creating a vulnerability where none existed before, by waking up the immune system.
How soon will we know if this actually works in people?
We have two trials running now. The prostate cancer trial has already seen what we'd call an exceptional response in the first patient. But one patient isn't a pattern. We need to see whether that holds across dozens, hundreds of patients. That takes time.
What's the biggest risk here—that it won't work, or that it will work but create new problems?
Both are real questions. But telmisartan has a long safety record. The risk isn't unknown. The real question is efficacy. Does the lab finding translate to the clinic? That's what we're testing now.